Table 2.

Baseline clinical features, followup duration, and antirheumatic medications among patients who achieved or did not achieve the state of inactive disease in the first 5 years after baseline. Values are medians (first and third quartiles) unless otherwise indicated.

No Inactive Disease,1 Episode of Inactive Disease,≥ 2 Episodes of Inactive Disease,
Featurenn = 62nn = 40nn = 21p
No. (%) male/female6218 (29)/44 (71)409 (23)/31 (78)215 (24)/16 (76)0.74a
ILAR category, n (%)6240210.16a
  Oligoarthritis extended23 (37.1)23 (57.5)10 (47.6)
   Polyarthritis17 (27.4)11 (27.5)4 (19)
   Systemic arthritis22 (35.5)6 (15)7 (33.3)
Age at disease onset, yrs624.2 (2.1; 6.6)403.3 (2; 6.4)213.9 (1.9; 4.8)0.67c
Disease duration, yrs620.8 (0.3; 1.8)390.4 (0.2; 1.5)210.6 (0.4; 1.9)0.40c
Interval disease onset–first observation, yrs620.8 (0.4; 1.8)400.5 (0.2; 1.5)210.6 (0.4; 1.9)0.41c
Interval first–last observation, yrs628.1 (6.8–10.5)407.0 (6.5–9.0)216.7 (6.4–7.4)0.06c
Interval disease onset–methotrexate start, yrs622.1 (0.8; 4.2)402.1 (0.8; 4.8)211.3 (0.6; 3.0)0.25c
Physician’s global assessment327.5 (7.5; 10)277.3 (4.6; 8.1)197.5 (6.1; 9.0)0.09c
Parent’s global assessment223.0 (2.0; 6.9)233.3 (1.5; 6.3)184 (1.7; 5.5)0.83c
Parent’s pain assessment135.0 (0.7; 6.0)213.4 (2.3; 6.5)153.3 (2.0; 5.0)0.97c
Swollen joint count594.0 (2.0; 10.0)383.0 (2.0; 5.0)217.0 (4.0; 17.0)0.009*c
Tender joint count593.0 (0.0; 9.0)382.5 (1.0; 5.0)216.0 (3.0; 16.0)0.02c
Restricted joint count594.0 (1.0; 9.0)383.5 (1.0; 6.0)216.0 (3.0; 8.0)0.17c
Active joint count595.0 (3.0; 14.0)384.0 (2.0; 7.0)217.0 (5.0; 22.0)0.02††c
CHAQ disability index390.6 (0.0; 1.0)280.5 (0.2; 1.1)190.8 (0; 1.3)0.59c
Erythrocyte sedimentation rate, mm/h5950 (32; 77)3843.5 (25; 67)2137 (22; 56)0.27c
C-reactive protein, mg/dl294.6 (0.6; 6.5)261.6 (0.7; 6.8)191.9 (0.4; 5.2)0.44c
Poznanski score, units33–0.86 (–1.6; –0.1)18–0.8 (–1; 0.1)13–0.5 (–1.3; 0.1)0.75c
Duration of methotrexate therapy, yrs**624.4 (3.6; 5.0)403.8 (3.1; 4.6)213.9 (3.2; 4.7)0.04***c
No. (%) patients who received cyclosporine**6231 (50.0)4011 (27.5)213 (14.3)0.005†††a
No. (%) patients who received sulfasalazine**6211 (17.7)407 (17.5)210 (0.0)0.09b
No. (%) patients who received etanercept**6211 (17.7)407 (17.5)211 (4.8)0.37b
No. (%) patients who received prednisone**6221 (33.9)409 (22.5)215 (23.8)0.40a
  • ILAR: International League of Associations of Rheumatology; CHAQ: Childhood Health Assessment Questionnaire. See Table 1 for score ranges of outcome measures.

  • ** In the first 5 years after first observation.

  • a chi-squared test;

  • b Fisher’s exact test;

  • c Kruskal-Wallis test. Post-hoc comparisons:

  • * swollen joint count is greater in patients with ≥ 2 episodes of inactive disease than in patients with 1 episode of inactive disease (Dunn’s test; p < 0.01);

  • tender joint count is greater in patients with ≥ 2 episodes of inactive disease than in patients with 1 episode of inactive disease (Dunn’s test; p < 0.05);

  • †† active joint count is greater in patients with ≥ 2 episodes of inactive disease than in patients with 1 episode of inactive disease (Dunn’s test; p < 0.05);

  • *** Dunn’s test not significant;

  • ††† frequency of cyclosporine therapy is greater in patients with no inactive disease than in patients with ≥ 2 episodes of inactive disease (chi-square with Bonferroni correction; p = 0.01).